Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.9K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K
Dementia01:30

Dementia

633
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
633
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

2.3K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.3K
Amyloid Fibrils03:03

Amyloid Fibrils

12.4K
Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
12.4K
Role of Neurotransmitters in Memory01:23

Role of Neurotransmitters in Memory

2.8K
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
 Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
2.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Family Caregivers of Adults Aged 80 and over: Caregiving as a Stress Process and a Disruption of Occupational Balance.

Healthcare (Basel, Switzerland)·2026
Same author

[Ageing in the age of misinformation: a public health challenge].

Geriatrie et psychologie neuropsychiatrie du vieillissement·2026
Same author

[Social isolation and loneliness among seniors: the place and role of psychologists].

Revue de l'infirmiere·2026
Same author

Perceived educational needs in geriatric medicine of professionals: a multinational multilingual open online survey.

European geriatric medicine·2026
Same author

Optimizing Antidepressant Use in Geriatric Depression: Expert Consensus from French societies of geriatrics, old age psychiatry and clinical pharmacy (SFGG, SF3PA and SFPC).

European psychiatry : the journal of the Association of European Psychiatrists·2026
Same author

Delirium awareness and care practices among Western European healthcare professionals: a survey.

European geriatric medicine·2026

Related Experiment Video

Updated: Mar 9, 2026

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

1.0K

[Alzheimer's disease today].

Sylvie Bonin-Guillaume1

  • 1Aix-Marseille Université, AP-HM, Hôpital Sainte-Marguerite, 270 boulevard de Sainte-Marguerite, 13009 Marseille, France.

Revue De L'Infirmiere
|January 4, 2017
PubMed
Summary

Neurodegenerative diseases like Alzheimer's present a significant societal challenge, impacting many lives and necessitating comprehensive support for patients and caregivers throughout disease progression.

Area of Science:

  • Neurology
  • Public Health
  • Gerontology

Background:

  • Neurodegenerative diseases pose a growing global health challenge.
  • Alzheimer's disease and related disorders affect a substantial portion of the population, particularly in France (over 850,000 individuals).
  • The profound effect on patient and caregiver quality of life underscores the need for improved care strategies.

Purpose of the Study:

  • To highlight the societal burden of neurodegenerative diseases.
  • To emphasize the critical need for enhanced support systems for Alzheimer's patients and their families.
  • To advocate for a coordinated approach to care across all disease stages.

Main Methods:

  • This study is a review and analysis of the societal impact of neurodegenerative diseases.
Keywords:
Alzheimer's diseaseannonceannouncementcarediagnosisdiagnosticmaladie d’Alzheimerprise en chargetraitementtreatment ;

More Related Videos

Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke
09:45

Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke

Published on: March 22, 2016

10.8K
Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model
06:02

Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model

Published on: July 26, 2011

37.5K

Related Experiment Videos

Last Updated: Mar 9, 2026

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

1.0K
Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke
09:45

Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke

Published on: March 22, 2016

10.8K
Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model
06:02

Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model

Published on: July 26, 2011

37.5K
  • Data on prevalence in France was examined.
  • The impact on quality of life was assessed through existing literature.

    • Main Results:

    • Neurodegenerative diseases represent a major societal challenge.
    • Alzheimer's disease affects a significant number of people in France.
    • Current support systems require augmentation to meet patient and caregiver needs.

    Conclusions:

    • A concerted, high-quality support effort is essential for individuals with neurodegenerative diseases.
    • Addressing the needs of patients and caregivers at every disease stage is crucial.
    • Societal commitment is required to mitigate the impact of these conditions.